According to a new report from Intel Market Research, the global Herpes Simplex Virus (HSV) Vaccines market was valued at USD 865 million in 2024 and is projected to reach USD 1,360 million by 2034, growing at a robust CAGR of 6.8% during the forecast period (2025–2034). This growth is driven by the increasing global prevalence of HSV infections, rising awareness about sexually...